TCGA-NC-A5HT-01A-11R-A26W-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.360
- MYC_TARGETS_V2+0.290
- HEDGEHOG_SIGNALING+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.160
- E2F_TARGETS+0.150
- G2M_CHECKPOINT+0.140
- KRAS_SIGNALING_DN+0.130
- DNA_REPAIR+0.080
- MYOGENESIS+0.070
- PI3K_AKT_MTOR_SIGNALING+0.060
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.550
- COMPLEMENT-0.460
- INFLAMMATORY_RESPONSE-0.440
- KRAS_SIGNALING_UP-0.420
- IL6_JAK_STAT3_SIGNALING-0.410
- IL2_STAT5_SIGNALING-0.360
- COAGULATION-0.330
- INTERFERON_GAMMA_RESPONSE-0.310
- TNFA_SIGNALING_VIA_NFKB-0.260
- UV_RESPONSE_DN-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR11296886 | — | — | 0.860 |
| 2 | TCGA-J1-A4AH-01A-31R-A24H-07 | — | cohortSQ2 | 0.851 |
| 3 | TCGA-WA-A7GZ-01A-11R-A34R-07 | — | — | 0.848 |
| 4 | TCGA-85-7696-01A-11R-2125-07 | — | cohortSQ2 | 0.845 |
| 5 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.837 |
| 6 | TCGA-85-A5B5-01A-21R-A26W-07 | — | cohortSQ2 | 0.836 |
| 7 | dd75267f-824e-4ddc-9056-cdf0f500d39b | — | — | 0.831 |
| 8 | SRR8518365 | — | E | 0.829 |
| 9 | TCGA-46-6026-01A-11R-1820-07 | — | cohortSQ1 | 0.826 |
| 10 | TCGA-22-4601-01A-01R-1443-07 | — | cohortSQ2 | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |